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ABSTRACT
Acute myeloid leukemia (AML) is a neoplasia characterized by the rapid expansion 
of immature myeloid blasts in the bone marrow, and marked by poor prognosis and 
frequent relapse. As such, new therapeutic approaches are required for remission 
induction and prevention of relapse. Due to the higher chemotherapy sensitivity and 
limited life span of more differentiated AML blasts, differentiation-based therapies 
are a promising therapeutic approach. Based on public available gene expression 
profiles, a myeloid-specific differentiation-associated gene expression pattern was 
defined as the therapeutic target. A XIAP inhibitor (Dequalinium chloride, DQA) was 
identified in an in silico screening searching for small molecules that induce similar 
gene expression regulation. Treatment with DQA, similarly to Embelin (another 
XIAP inhibitor), induced cytotoxicity and differentiation in AML. XIAP inhibition 
differentially impaired cell viability of the most primitive AML blasts and reduced 
clonogenic capacity of AML cells, sparing healthy mature blood and hematopoietic 
stem cells. Taken together, these results suggest that XIAP constitutes a potential 
target for AML treatment and support the evaluation of XIAP inhibitors in clinical 
trials. 
INTRODUCTION 
Acute myeloid leukemia (AML) is a hematological 
neoplasia characterized by an abnormal growth and 
differentiation of immature myeloid cells that accumulate 
in bone marrow and interfere with the production of 
normal blood cells [1]. In spite of some improvement in 
its therapy, a minority of adults with AML are eventually 
cured, a fact stressing the need for new therapeutic 
approaches. 
AML is thought to be organized as a hierarchy 
of functionally heterogeneous cells that is ultimately 
sustained by a small fraction of leukemic stem cells 
(LSCs) with enhanced self-renewal capacity, impaired 
differentiation ability and increased drug resistance [2]. 
Among all AML blasts constituting the bulk tumor, only 
LSCs initiate and sustain the disease. As the balance 
between self-renewal and differentiation is tightly 
regulated and favours the former in LSCs, induction of 
terminal differentiation of LSCs would exhaust the LSC 
pool [3, 4]. Since differentiating therapy could induce 
higher chemotherapy sensitivity and limited life span of 
more differentiated AML blasts, combinatorial strategies 
of differentiating and cytotoxic agents with the capability 
to eliminate LSCs are a promising therapeutic approach, 
which could result in a significant improved outcome of 
AML patients [5]. 
Although global mechanisms that block 
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differentiation and increase self-renewal of AML cells are 
poorly understood, biological changes induced by agents 
that differentiate AML cells to diverse lineages are already 
described. Bioinformatics studies provided us the gene 
expression profile associated to granulocyte differentiation 
of AML cells treated with all-trans-retinoic acid (ATRA). 
This drug-induced gene expression pattern constituted 
the therapeutic goal in the search of agents with AML 
differentiating capacity. Following this approach and using 
Connectivity Maps [6], we identified the XIAP inhibitor 
Dequalinium chloride (DQA). XIAP inhibition induced 
cytotoxicity and differentiation in AML cells. Moreover 
DQA treatment preferentially affected leukemic stem 
cells, suggesting that targeting XIAP may contribute to 
eradicate the LSC population thought to be responsible for 
refractoriness and relapse episodes in AML and supporting 
further validation in pre-clinical and clinical studies.
RESULTS
In order to identify drugs that could induce myeloid 
differentiation in AML cells, a gene signature associated 
with ATRA-induced granulocytic differentiation of HL-
60 AML cells was defined using public available gene 
expression profiles (GSE982). Differentially expressed 
probe sets were identified (Supplementary Table 1) and 
the given gene signature (Supplementary Table 2) was 
used to query and compare against the reference catalogue 
of gene expression profiles obtained after drug or other 
perturbagen treatment of cell lines using the Connectivity 
Map (http://www.broadinstitute.org/cmap/) [6]. The 
results were filtered at a P value <0.05; connectivity score 
> 0.75 in HL-60, and > 0.5 in PC3 and MCF7; and a 
concentration < 10 µM in all cell lines (Supplementary 
Table 3). Dequalinium chloride (DQA, CAS no. 522-51-0) 
was the only compound that met all the above-described 
criteria. DQA is an amphiphilic quinolinium derivative 
(Supplementary Figure 1). 
We next studied the cytotoxic potential of DQA 
on well-characterized AML cell lines (HL-60, KG-1, 
MonoMac-1 and Kasumi-1). DQA induced cell death 
in all AML cell lines tested in a dose-response fashion 
after a 3-day treatment, achieving more than 50% of 
cell death at the highest concentration (5 µM) (Figure 
1A). Since accumulating evidence shows that the bone 
marrow stromal environment might protect leukemia 
cells from chemotherapy-induced apoptosis, the cytotoxic 
potential of DQA was also tested on AML cell lines co-
cultured with the HS-5 human bone marrow stroma cell 
line. Cellular viability of DQA-treated AML cells was 
impaired regardless the presence of HS-5 stroma cells 
(Figure 1A). Moreover, the proportion of cell death 
induced by DQA was similar regardless the presence of 
stroma cells, suggesting that the HS-5 stroma cells, that 
conferred chemoresistance to commonly used drugs such 
as ara-C and idarubicin [7], are unable to protect AML 
cell to the cytotoxic effect of DQA treatment. DQA was 
identified as a potential differentiation-inducer agent in 
our in silico screen. CD15 is up regulated in AML cells 
when differentiation is restored [8]. In all AML cell lines 
tested, DQA induced the upregulation of the CD15 surface 
marker (Figure 1B). These findings validated our in silico 
prediction of DQA as a differentiation-inducing drug of 
AML cells.
DQA has been identified as a XIAP inhibitor by its 
direct binding [9]. In order to confirm that XIAP inhibition 
was responsible for the cytotoxic and differentiation 
effects observed upon DQA treatment, a well-described 
XIAP inhibitor embelin was chosen[10]. As shown with 
DQA, embelin induced cytotoxicity and upregulation 
of CD15 surface expression (Figure 1C). In fact, both 
inhibitors reduced the amount of XIAP upon treatment 
(Figure 1D). Moreover, DQA and embelin treatment 
decreased the clonogenic capacity of AML cells (Figure 
1E). These results suggest that XIAP inhibition overcomes 
the block in differentiation displayed by AML cells and 
reduces cell viability.
A way to promote differentiation is achieved 
through prevention of S-phase entry. This mechanism of 
action has been described for ATRA [11]. Similarly to 
ATRA, DQA treatment induced cell-cycle arrest in the G0/
G1 phase whereas a reduction in G2/M phase was detected 
upon treatment of AML cell lines (Figure 2A and 2B). 
Several signaling pathways are misregulated in 
AML. Activation of Erk and Akt pathways [12, 13] 
have been considered as critical for the survival and/or 
proliferation of AML cells. In this context, DQA treatment 
was observed to reduce the amount of activated signaling 
molecules in all AML cell lines tested after intracellular 
staining of P-Akt and P-Erk (Figure 2C and 2D). These 
results correlate with the observed cytotoxic effect of 
DQA, which might at least in part be due to Akt and Erk 
downregulation.
Next, the cytotoxicity of DQA and embelin 
treatment was evaluated in samples of patients with AML. 
The presence of these inhibitors reduced cell viability 
24 and 72 h after treatment in the bulk AML population 
in a dose-dependent fashion (Figure 3A). Since the 
majority of the LSC population expresses the immature 
surface marker CD34 in the absence of CD38 [14], this 
marker combination (CD34+CD38-) was used to analyse 
the preferential effect of the drug on the LSC-enriched 
primitive population. Within the CD34+CD38- population, 
the reduction in cell viability was higher in the presence 
of DQA or embelin compared to the remaining leukemic 
blast population (Figure 3A), suggesting that XIAP 
inhibitor cytotoxic effect is preferentially displayed on 
the stem-cell like or primitive population. Interestingly, 
no effect was detected when healthy myeloid blood 
cells were incubated with DQA or embelin (Figure 3B). 
Taking into account that XIAP expression has been 
described as a prognostic marker [15, 16], we analysed the 
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Figure 1: XIAP inhibitor treatment induces cytotoxicity and differentiation on AML cell lines. A. Cytotoxicity in HL-60, 
MonoMac-1 (MM) and Kasumi-1 (K-1) AML cell lines resulting from treatment with 5 µM DQA for 48 h in the absence (upper panel) or 
presence of HS-5 stroma cells (lower panel). Y-axis: relative number of live cells as assessed by flow cytometry (7-AAD-). B. Up-regulation 
of CD15 surface expression, measured by flow cytometry in AML cell lines (HL-60, KG-1, MonoMac-1 and Kasumi-1) treated with 5 µM 
DQA. Data from all AML cell lines are presented combined. Frequency of CD15-positive population normalized against control-treated 
samples is represented. CD15 surface expression representative plot of HL-60 untreated (left) or treated with 5 µM DQA (right). C. HL-
60, Kasumi-1, MonoMac-1 and KG-1 AML cells were treated with different concentrations of Embelin for 48 h. Cell viability (upper left 
panel) and CD15 surface expression (upper right panel) were measured by flow cytometry. Representative flow cytometry plot of HL-60 
untreated (left) or treated with 10 µM Embelin (right). D. XIAP protein was detected by Western blot upon DQA (D) and Emb (E) treatment 
of HL-60 cells. GAPDH was used as loading control. MFI refer to GAPDH and vehicle-treated control is represented. E. HL-60 cells were 
treated for 18 h with 5 µM DQA (left) and 10 µM embelin (right). Colonies were counted at day 7. * p<0.05; ** p<0.005; *** p<0.0005. 
Error bars correspond to SEM.
Oncotarget4340www.impactjournals.com/oncotarget

















#1 M 28 AML without maturation 143 98 90 46, XY FLT3-ITD




#3 F 34 AML with myelodysplasia-related changes 32 16 44 45,XX, -7
FLT3wt 
NPMwt
#4 M 45 AML with t(6,9) 40 58 43 46,XY,t(6;9)(p23;q34) FLT3-ITD
#5 M 48 AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 54 5 24 46,XY,t(8;21)(q22;q22)
NPMwt  / 
FLT3 N/A










#8 M 24 AML with myelodysplasia-related changes 7.1 83 30 46,XY[20]
FLT3wt 
NPMwt 








#10 M 22 AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 20.4 83 69
45,X,-Y,t(8;21)(q22;q22)
[17]/46,XY[3] FLT3 ITD
#11 F 60 AML with myelodysplasia-related changes 218.1 68 36 48,XX,+8,+21[13]
FLT3wt 
NPMwt 
Figure 2: DQA treatment induces cell cycle arrest and downregulation of P-Akt, P-Erk and P-Stat3. HL-60, KG-1, 
MonoMac-1 and Kasumi-1 were treated with 5 µM DQA and cell cycle was analyzed by flow cytometry 48 h after treatment. A. Relative 
frequency of G0/G1, S and G2/M phases in control- vs. DQA-treated AML cells. Bars represent the mean value of all AML cell lines and 
error bars represent SEM. B. Representative DNA content flow profile of control- (left) and DQA-treated (right) HL-60 (green represents 
G0/G1 phase; yellow, S phase; blue, G2/M phase). P-Akt and P-Erk expression levels by flow cytometry in AML cell lines after treatment 
with 5 µM DQA for 24 h. C. Mean fluorescence intensity of each staining was normalized against vehicle-control treated sample and 
data from all AML cell lines tested is represented. D. Representative flow histograms of P-Akt (left), P-Erk (centre) and P-Stat3 (right) 
intracellular staining of DQA-treated HL-60 AML cells. Shadow, negative control; solid line, control treated sample; dashed line, DQA-
treated sample. * p<0.05; ** p<0.005. 
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cytotoxic effect of DQA treatment on the most primitive 
AML blast cell fraction within each prognostic group 
[17]. In concordance with protein expression data [15], 
intermediate and unfavourable risk groups were more 
sensitive to DQA treatment (Figure 3C). 
Moreover, clonogenic capacity, which constitutes 
a direct measure of stem cell function [18], was reduced 
after DQA and embelin treatment of AML primary cells 
(Figure 4A). Treatment of lineage-depleted umbilical cord 
blood cells with DQA or embelin had little effect on the 
clonogenic capacity, as measured by the total number of 
colonies or the frequency of each subtype (Figure 4B). 
Figure 3: DQA and embelin treatment induces cell death in AML primary blasts by preferentially affecting LSC 
population and reduces clonogenic capacity. AML primary blasts A. or healthy myeloid blood cells B. were treated with different 
concentration of DQA (0.05, 0.5, 5 µM) and embelin (0.1, 1, 10 µM). Cell viability was analysed at day 1 (upper panels) and 3 (lower panels) 
after treatment. Each symbol corresponds to a single AML patient sample, specified in the graph legend. Bulk population corresponds 
to AML blast cells and the primitive fraction corresponds to a CD34+CD38- blast population. C. Primary AML patient samples were 
treated for 24 h with 5 mM DQA. Cell viability was measured by flow cytometry (volumetric counts on live 7-AAD- cells). Each symbol 
corresponds to an AML patient sample. Green, favourable risk group; blue, intermediate risk group; red, unfavourable risk group. * p<0.05; 
** p<0.005; *** p<0.0005.
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Taken together, these results suggest that XIAP inhibition 
preferentially impairs LSC functionality in AML. 
DISCUSSION
Although the notion that induction of differentiation 
by chemical agents in leukemic cells could reprogram 
the cells toward proliferation arrest and/or programmed 
cell death was established four decades ago [19, 20], only 
retinoic acid for the treatment of acute promyelocytic 
leukemia has revealed as a successful clinical application 
of this hypothesis. We performed an in silico screening 
seeking for FDA-approved drugs that produced a 
gene expression regulation similar to ATRA in HL-60 
AML cells. A XIAP inhibitor, DQA, was identified and 
validated both in different AML cells lines and primary 
patient samples. XIAP inhibition also induced myeloid 
differentiation and cell death in AML cells. Interestingly, 
the clonogenic capacity was severely reduced upon 
treatment. Additionally, the most primitive fraction of 
AML blasts appeared to be more cytotoxic-sensitive to 
XIAP inhibition than more mature blasts. Interestingly, 
little effect was detected in healthy blood cells and 
primitive lineage-negative cord blood cells.
DQA is a classic broad bacteriostatic with anti-
fungicidal and anti-protozoal activity [21, 22]. At a 
molecular level, DQA interrupts the interaction XIAP/
Caspase-3 [9]. XIAP protein and mRNA levels have been 
correlated with chemoresistance [23] and poor clinical 
outcome in AML patients [15, 16], suggesting that XIAP 
may constitute an interesting therapeutic target for AML 
treatment. In fact, only most aggressive AML patient 
samples seemed to respond to DQA treatment. Phase I/
II clinical trials evaluating the effect of a XIAP antisense 
oligonucleotide showed that this strategy seems to be 
effective when combined with chemotherapy in patients 
with AML refractory to a single induction regimen[24]. 
Interestingly, DQA-mediated cytotoxic effect seems to be 
stroma-independent. Microenvironment has been linked 
with primary LSC resistance to therapy where the niche 
signaling could regulate cell cycle and chemoresistance 
[25]. Here, XIAP inhibitors are described as AML 
differentiation inducer and, consequently, a reduction 
in clonogenic capacity and cell cycle arrest is produced. 
Similarly, other cell cycle arrest-inducing and pro-
apoptotic drugs are effective in pre-clinical studies [26]. 
XIAP inhibitors already approved for clinical use, such 
as DQA, may be of great interest to explore their anti-
leukemia effect and their potential therapeutic use in 
combination with conventional chemotherapy.
AML is hierarchically organized, with quiescent 
“stem-cell”-like cells (LSCs) at the apex, that have the 
ability to perpetuate themselves through self-renewal and 
generate more mature progeny through differentiation [2]. 
According with this model, the inability to eradicate LSCs 
represents the cause of relapse and therapeutic failure. 
Thus, effective tumor therapy will require eradication 
of these cells. Designing agents that can differentiate 
leukemia cells into non-dividing/non-malignant growth-
arrested cells constitutes a new experimental approach 
for non-APL AML treatment. Here, XIAP inhibitors 
are described as AML differentiation inducer and, 
consequently, a reduction in clonogenic capacity and cell 
cycle arrest is produced. Therefore, there is a cessation 
of self-renewal capacity and XIAP may constitute a 
therapeutic target. Similarly, Bcl2L10 (another anti-
Figure 4: XIAP inhibitor treatment reduced the clonogenic capacity of AML cells with little effect on primitive healthy 
blood cells. D. AML primary cells or E. lineage-depleted umbilical cord blood cells were treated with 5 µM DQA or 10 µM embelin for 
18 h. Colonies were screened at day 14 based on morphological criteria. Each symbol represents primary sample. * p<0.05; ** p<0.005; 
*** p<0.0005.
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apoptotic molecule) has also been described as a 
therapeutic target for AML and MDS [27]. Interestingly, 
an inhibitor against both Bcl-2 and Bcl-X, ABT-737, 
displayed anti-leukemia effect on AML [28]. Moreover, 
Pten/mTOR and the PI3K/Akt signalling pathway have 
been shown to be implicated in AML development and 
leukemia stem cell population maintenance [13, 29]. Here, 
XIAP inhibition reduced P-Akt levels in concordance with 
previous work and may explain the differential effect on 
the LSC population. XIAP inhibitors already approved 
for clinical use, such as DQA, may be of great interest 
to explore their anti-leukemia effect and their potential 
therapeutic use in combination with conventional 
chemotherapy. 
In summary, our in silico screen for differentiation-
inducing agents lead to the identification of DQA, an agent 
with a known capacity of XIAP inhibition. Interestingly, 
XIAP inhibitors proved to result in a significant cytotoxic 
and differentiating activity both in AML cell lines 
and primary samples, with a preferential effect on the 
immature leukemic stem-cell fraction and sparing healthy 
blood cells. These findings warrant further investigation 
in pre-clinical and clinical setting, in combination with 
currently used chemotherapy. 
MATERIALS AND METHODS
Identification of genes related to myeloid 
differentiation with Connectivity Maps
Gene signature associated with ATRA-induced 
differentiation in HL-60 cells was obtained from GSE982. 
Raw files (.cel) were normalized and probe sets with a 
differential expression of at least 2-fold of change and 
p value <0.005 were chosen (Supplementary Table 1) 
using GenePattern software (Broad Institute Cancer 
Program; http://www.broadinstitute.org/cancer/software/
genepattern/). The 49 top-ranking downregulated and 269 
top-ranking upregulated probes during ATRA treatment 
were selected for in silico signature-based screening 
(Supplementary Table 2) (Connectivity Maps; http://www.
broadinstitute.org/cmap/).
AML cell lines and cell cultures 
AML cell lines HL-60 (ACC-3)[30], KG-1 (ACC-
14)[31], MonoMac-1 (ACC-252)[32] and Kasumi-1 
(ACC-220)[33] were obtained from DSMZ (Deutsche 
Sammlung von Mikroorganismen und Zellkulturen) and 
the human stroma cell line HS-5 was purchased from 
ATCC (American Type Culture Collection). Experiments 
were performed within 6 months after receipt or 
resuscitation. AML cell lines were cultured in complete 
RPMI medium (PAA laboratories) supplemented with 
fetal bovine serum (Lonza), sodium pyruvate (Lonza) 
and/or non-essential amino acids (Lonza) according to 
manufacturers’ recommendations. HS-5 cell line was 
cultured in complete DMEM medium (PAA laboratories) 
supplemented with 10% fetal bovine serum (Lonza). 
Primary AML blasts were cultured in IMDM (PAA 
laboratories) supplemented with 3% heat-inactivated fetal 
bovine serum (Lonza), 1x BIT (StemCell Technologies), 
5 ng/ml IL3 (Peprotech), sodium pyruvate (Lonza) and 
β-mercaptoethanol (Sigma). 
Primary samples
Primary AML samples were obtained from 
patients diagnosed with AML at Hospital Clínic of 
Barcelona (Spain). AML diagnosis and classification was 
based on accepted WHO criteria. Main AML patient’s 
characteristics are summarized in Table 1. Samples 
were obtained from bone marrow and mononuclear 
cells (MNCs) were isolated by Ficoll density gradient 
centrifugation (GE). All patients provided written 
informed consent in accordance with the Declaration 
of Helsinki, and the study was approved by the Ethics 
Committee of Hospital Clínic of Barcelona. Blood mature 
MNCs were isolated from healthy-donor buffy coats 
provided by Banc de Sang i Teixits (Barcelona, Spain). 
Umbilical cord blood MNCs were obtained after Ficoll 
density gradient centrifugation and were depleted for 
lineage marker-positive cells (Milteny). 
Drugs
Dequalinium chloride hydrate was obtained from 
Sigma-Aldrich, resuspended in ultrapure H2O (Sigma) 
and stored at -20ºC at 5mM. Embelin was purchased from 
Enzo Life Science, resuspended in DMSO and stored at 
-20ºC at 10 mM. 
Citotoxicity assay
Five-hundred thousand cells per ml were cultured in 
96-well plates in complete medium. DQA or embelin were 
added at different concentrations. Co-culture experiments 
were performed seeding 30 x 103 HS-5 cells with 1 x 105 
AML cells per 200 µl of complete medium. Cell viability 
was measured by 7-AAD (eBioscience) exclusion by flow 
cytometry and cell count was obtained by volume in a 
FACSVerse cytometer (BD). In co-culture experiments, 
AML cells were discriminated based on CD45 expression. 
Statistical analysis and IC50 determination were calculated 
in GraphPad (Prism software). FlowJo software (TriStar) 
was used for flow cytometry analysis. 
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Myeloid differentiation
Cells were treated as indicated for cytotoxicity 
assays. Forty-eight hours after treatment, cells were 
stained with anti-human CD15-APC (BD) and surface 
expression of the antigen was analyzed by flow cytometry 
(FACSVerse, BD). 
Western Blot
HL-60 cells (10 x 106 cells) were incubated with 5 
µM DQA or 10 µM embelin for 48 h. Cells were harvested 
and lysed in RIPA buffer. The protein extract was subjected 
to SDS-polyacrylamide gel (BioRad) electrophoresis and 
transferred to PVDF membrane (BioRad). Mouse anti-
XIAP and goat anti-GAPDH antibodies were purchased 
from BD and Abcam respectively. 
Cell cycle analysis
Cells were cultured and treated with DQA as 
described above for experiments of differentiation 
induction. Twenty-four hours after treatment, cells 
were harvested, washed with PBS (Sigma), and fixed 
and permeabilized in 70% ethanol (Sigma) at 4ºC. 
DNA content was stained with 7-AAD (eBioscience) 
and measured by flow cytometry (FACSVerse, Becton 
Dickinson). Data were analyzed using Watson cell cycle 
model in FlowJo 7.6.5.
Intracellular staining
Cells were fixed with 2% formaldehyde 
(Applichem Lifescience), permabilized with 100% 
methanol (VWR BDH Prolabo), and stained with anti-
Phospho-Akt (Thr308) clone C31E5E and anti-Phospho-
Erk1/2 (Thr202/Tyr204) clone E10 from Cell Signaling 
Technologies following manufacturers’ recommendations. 
RPE-coupled goat anti-mouse and anti-rabbit secondary 
antibodies (Life Technologies) were used and samples 
were acquired in a FACSVerse cytometer (BD). FCS files 
were analyzed in FlowJo software (TriStar). 
Clonogenic assay
Primary AML (50 x 103) or HL-60 (1 x 103) cells 
were treated for 18 h with the compound indicated 
and mixed with 1 mL of MethoCult H4034 Optimum 
(StemCell Technologies). Colonies were screened based 
on morphology and cellularity at day 5 (AML cell lines) 
or day 14 (primary AML cells).
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